Literature DB >> 21621000

Human FoxP3+ regulatory T cells in systemic autoimmune diseases.

Makoto Miyara1, Guy Gorochov, Michael Ehrenstein, Lucile Musset, Shimon Sakaguchi, Zahir Amoura.   

Abstract

Since the characterization of CD4(+)CD25(+) regulatory T (Treg) cells in mice, significant progress has been made in the definitions of the phenotype and the function of human Treg cells in health and in pathological conditions. Recent advances in the field leading to a better molecular definition of Treg subsets in humans and the description of the dynamics of differentiation of Treg cells should bring new insights in the understanding of human chronic systemic autoimmune diseases. How Treg cells are compromised in these diseases is a challenging issue because the elucidation of the mechanisms leading to such anomaly might lead to promising novel therapeutic approaches.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621000     DOI: 10.1016/j.autrev.2011.05.004

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  123 in total

1.  Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance.

Authors:  Jane E Klann; Stephanie H Kim; Kelly A Remedios; Zhaoren He; Patrick J Metz; Justine Lopez; Tiffani Tysl; Jocelyn G Olvera; Jailal N Ablack; Joseph M Cantor; Brigid S Boland; Gene Yeo; Ye Zheng; Li-Fan Lu; Jack D Bui; Mark H Ginsberg; Brian G Petrich; John T Chang
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

2.  Exacerbation of spontaneous autoimmune nephritis following regulatory T cell depletion in B cell lymphoma 2-interacting mediator knock-out mice.

Authors:  Y M Wang; G Y Zhang; Y Wang; M Hu; J J Zhou; A Sawyer; Q Cao; Y Wang; G Zheng; V W S Lee; D C H Harris; S I Alexander
Journal:  Clin Exp Immunol       Date:  2017-02-28       Impact factor: 4.330

3.  Diversification and senescence of Foxp3+ regulatory T cells during experimental autoimmune encephalomyelitis.

Authors:  Sharyn Tauro; Phuong Nguyen; Bofeng Li; Terrence L Geiger
Journal:  Eur J Immunol       Date:  2013-04-09       Impact factor: 5.532

Review 4.  TREG-cell therapies for autoimmune rheumatic diseases.

Authors:  Makoto Miyara; Yoshinaga Ito; Shimon Sakaguchi
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

Review 5.  Regulatory T cells in autoimmune disease.

Authors:  Margarita Dominguez-Villar; David A Hafler
Journal:  Nat Immunol       Date:  2018-06-20       Impact factor: 25.606

Review 6.  The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases.

Authors:  A Mohr; M Atif; R Balderas; G Gorochov; M Miyara
Journal:  Clin Exp Immunol       Date:  2019-03-24       Impact factor: 4.330

7.  Administration of CD4+CD25highCD127-FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study.

Authors:  Kamil Chwojnicki; Dorota Iwaszkiewicz-Grześ; Anna Jankowska; Maciej Zieliński; Paweł Łowiec; Mateusz Gliwiński; Małgorzata Grzywińska; Kamil Kowalczyk; Aleksandra Konarzewska; Paulina Glasner; Justyna Sakowska; Julia Kulczycka; Anna Jaźwińska-Curyłło; Marlena Kubach; Bartosz Karaszewski; Walenty Nyka; Edyta Szurowska; Piotr Trzonkowski
Journal:  BioDrugs       Date:  2021-01-05       Impact factor: 5.807

8.  Talin Plays a Critical Role in the Maintenance of the Regulatory T Cell Pool.

Authors:  Jane E Klann; Kelly A Remedios; Stephanie H Kim; Patrick J Metz; Justine Lopez; Lauren A Mack; Ye Zheng; Mark H Ginsberg; Brian G Petrich; John T Chang
Journal:  J Immunol       Date:  2017-05-17       Impact factor: 5.422

Review 9.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 10.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.